References
- March, M. and Bachmeier, C. J. (1997). Economics of osteoarthritis: a global perspective. Balliere's Gun. Rheumatol., Vol. II, Chapt. 4, pp. 817–834.
- Hill, C. L., Parsons, J., Taylor, A. and Leach, G. (1999). Health related quality of life in a population sample with arthritis. J. Rheumatol., 26(9), 2029–2035.
- Zeb, S. and Edwards, L. (1998). Osteoarthritis: nonpharmacologic therapy. UM. Rev., Summer, 14–17.
- Emery, P. (1996). Considerations for nonsteroidal anti-inflammatory drug therapy: benefits. Scand. J. Rheumatol., 25 (Suppl 105), 5–12.
- Hayliar, J., Macpherson, A. and Bjarnason, I. (1992). Gastroprotection and non-steroidal anti-inflammatory drugs. Drug Safety, 7, 86–105.
- Moore, R. A. and Phillips, C. J. (1999). Cost of NSAID adverse effects to the UK National Health Service. J. Med. Econ., 2, 45–55.
- LaMe, L., Harper, S., Simon, T., Bath, R., Johanson, J., Schwartz, H. et al. (1999). A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology, 117, 776–783.
- Lanza, F. L., Rack, M. R., Simon, T. J., Quan, H., Bolognese, J. A., Hoover, M. E. et al. (1999). Specific inhibition of cyclo-oxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment. Pharmacol. Ther, 13, 761–777.
- Langman et al. (1999). Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA, 282, 1929–1933.
- Vane, J. (1994). Towards a better aspirin. Nature, 376, 215–216.